Functional and Anatomical Visual Investigations in Patients With Early Forms of Age-related Macular Degeneration

NCT ID: NCT06694272

Last Updated: 2025-04-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-04-09

Study Completion Date

2031-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Age-related macular degeneration (AMD) is the leading cause of visual impairment in industrialized countries. Anatomical examination findings at the early and intermediate stages of AMD are not sufficient to determine any functional alterations at these stages (e.g., alterations in microperimetry, multifocal electroretinogram (mfERG) and contrast sensitivity). Identifying early functional markers of the disease is a necessary first step in the development and clinical validation of treatments to slow progression to advanced disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Age Related Macular Degeneration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

subjects with early or intermediate AMD (normal visual acuity)

At inclusion patients will have :

* Measurements of subjective refraction, visual acuity, intraocular pressure, slit-lamp examination
* Measurement of low-luminance visual acuity
* Measurement of low-light contrast sensitivity
* Photometric (\> 30 cd/m² \> 10 min) and scotopic (DA \> 20 min) microperimetry
* Multifocal electroretinogram
* Imaging using fundus photography, OCT, OCT-A, adaptive optics and autofluorescence
* Venous blood sampling (48 mL)

After 4 years of follow-up, AMD evolution will be assessed with :

* Measurements of subjective refraction, visual acuity, intraocular pressure, slit-lamp examination
* Imaging by fundus photography, OCT, OCT-A, and autofluorescence

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient over 18 years of age
* Corrected visual acuity 10/10 in each eye
* Presence of retinal alteration(s) compatible with early (presence of macular drusen \< 125 μm) or intermediate (macular drusen \> 125 μm or pigmentary abnormalities) AMD in at least one of the two eyes :

* Conventional "soft" or "hard" drusen
* Cuticular drusen
* Reticulated pseudo-drusen

Exclusion Criteria

* Presence of geographic atrophy, even incipient, in one or both eyes
* Presence of patent or latent neovascularization visible on OCT b-scan or OCT-A in one or both eyes
* Compatibility of retinal signs with a "probable" differential diagnosis (bestrophinopathies, familial drusen, fundus flavimaculatus, fundus albipunctatus, hypovitaminosis A) in one or both eyes.
* Oculomotor pathology that may prevent proper performance of functional tests: nystagmus, oculomotor paralysis, in one or both eyes
* Neurological/neurodegenerative pathology that may prevent adequate performance of functional tests: advanced Parkinsonian syndromes, Benson's disease, Alzheimer's disease with visuomotor apraxia
* Other ophthalmological pathology that may affect anatomical and functional measurements: hypertonia / glaucoma or other optic neuropathy, media disorder causing reduced visual acuity, refraction \< -6.00D or \> +6.00D
* Other medical conditions preventing examinations or imaging (tremors, etc.)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fondation Ophtalmologique Adolphe de Rothschild

NETWORK

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hôpital Fondation A. de Rothschild

Paris, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Amelie Yavchitz

Role: CONTACT

+33148036454

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sophie Bonnin

Role: primary

(0)148036437 ext. +33

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SBN_2024_7

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.